MedPath

Providence Health & Services

Providence Health & Services logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1859-01-01
Employees
10K
Market Cap
-
Website
http://www.providence.org

Clinical Trials

81

Active:19
Completed:32

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:30
Phase 2:19
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials

Phase 1
30 (42.9%)
Phase 2
19 (27.1%)
Not Applicable
12 (17.1%)
Phase 3
5 (7.1%)
Phase 4
3 (4.3%)
Early Phase 1
1 (1.4%)

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Radiation: Chemoradiation
Drug: FOLFOX regimen
First Posted Date
2024-12-05
Last Posted Date
2025-07-10
Lead Sponsor
Providence Health & Services
Target Recruit Count
110
Registration Number
NCT06719362
Locations
🇺🇸

Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Phase 2
Not yet recruiting
Conditions
Triple Negative Breast Cancer
Interventions
First Posted Date
2024-04-09
Last Posted Date
2024-07-26
Lead Sponsor
Providence Health & Services
Target Recruit Count
12
Registration Number
NCT06353997
Locations
🇺🇸

Ellison Institute of Technology (EITM), Los Angeles, California, United States

🇺🇸

Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States

🇺🇸

Providence St. Vincent Medical Center, Portland, Oregon, United States

and more 1 locations

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Phase 2
Recruiting
Conditions
Primary Central Nervous System Lymphoma
Interventions
Procedure: Cognitive Assessment
Other: Quality of Life Assessment
First Posted Date
2023-12-18
Last Posted Date
2025-06-05
Lead Sponsor
Providence Health & Services
Target Recruit Count
28
Registration Number
NCT06175000
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

Providence Health & Services; Providence Neurological Specialties, Portland, Oregon, United States

and more 4 locations

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Metastatic Melanoma
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2023-06-22
Last Posted Date
2025-03-11
Lead Sponsor
Providence Health & Services
Target Recruit Count
92
Registration Number
NCT05913388
Locations
🇺🇸

Providence Portland Medical Center, Portland, Oregon, United States

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

Active, not recruiting
Conditions
Breast Cancer
First Posted Date
2022-08-19
Last Posted Date
2025-03-10
Lead Sponsor
Providence Health & Services
Target Recruit Count
15
Registration Number
NCT05508984
Locations
🇺🇸

Providence Cancer Institute - Newberg Clinic, Newberg, Oregon, United States

🇺🇸

Providence Portland Medical Center, Portland, Oregon, United States

🇺🇸

Providence Oncology and Hematology Care - Westside, Portland, Oregon, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 17
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.